Piper Jaffray Downgrades Regeneron (REGN) to Neutral

Piper Jaffray downgraded Regeneron Pharma (NASDAQ: REGN) from Overweight to Neutral, price target maintained at $81.

For an analyst ratings summary and ratings history on Repligen click here. For more ratings news on Repligen click here.

---

Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!

You May Also Be Interested In

• UPDATE: UBS Downgrades Wisconsin Energy (WEC) to Neutral; Taking Some Off The Table
• Wedbush Downgrades Maxwell Technologies (MXWL) to Neutral; Elevated Competitive and Supply Chain Risks

Create E-mail Alert Related Categories

Downgrades

Related Entities

Piper Jaffray

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?

Follow StreetInsider.com On Twitter